Sign up to save your podcasts
Or
Share JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
More shows like JAMA Network
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
318 Listeners
AFP: American Family Physician Podcast
697 Listeners
JAMA Clinical Reviews
498 Listeners
Medicine and Science from The BMJ
37 Listeners
Diabetes Core Update
106 Listeners
Mayo Clinic Talks
296 Listeners
The Curbsiders Internal Medicine Podcast
3,341 Listeners
JAMA Pediatrics Editors' Summary
38 Listeners
JAMA Neurology Author Interviews
12 Listeners
JAMA Dermatology Author Interviews
16 Listeners
JAMA Internal Medicine Author Interviews
19 Listeners
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
7 Listeners
Core IM | Internal Medicine Podcast
1,149 Listeners
JAMAevidence The Rational Clinical Examination
30 Listeners
Annals On Call Podcast
193 Listeners
JAMA Medical News
94 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Cardionerds: A Cardiology Podcast
428 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
18 Listeners
The Curious Clinicians
370 Listeners
NEJM AI Grand Rounds
61 Listeners